Aβ modulation: The next generation of AD therapeutics

Annals of the New York Academy of Sciences

Volumn 920, Issue , 2000, Pages 269-273

  Felsenstein, Kevin M ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PRESENILIN 1; PRESENILIN 2; PROTEIN SYNTHESIS INHIBITOR;

ALZHEIMER DISEASE; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG COST; DRUG SCREENING; GENE MUTATION; HUMAN; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN PROCESSING; ARTICLE; DRUG DESIGN; DRUG EFFECT; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; DRUG DESIGN; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 0034353148     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06935.x     Document Type: Conference Paper

References (8)

1. Translating cell biology into therapeutic advances in Alzheimer's disease
2. A review of quality of life in Alzheimer's disease. Parts 1 and 2: Issues in assessing disease impact and drug effects
3. The presenilins in Alzheimer's disease: Proteolysis holds the key
4. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease
5. Modulation of amyloid β-protein precursor processing as a means of retarding progression of Alzheimer's disease
6. Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism
7. Cellular mechanisms of beta-amyloid production and secretion
8. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice